Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2018 | 1 |
2019 | 1 |
2024 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
Lancet Haematol. 2018 Dec;5(12):e609-e617. doi: 10.1016/S2352-3026(18)30177-7.
Lancet Haematol. 2018.
PMID: 30501868
Free PMC article.
Clinical Trial.
Hybrid dosing of the cyclin-dependent kinase (CDK) inhibitor flavopiridol in relapsed/refractory mantle cell lymphoma and diffuse large B-cell lymphoma.
Miljkovic MD, Roschewski M, Dunleavy K, Wilson WH.
Miljkovic MD, et al.
Leuk Lymphoma. 2019 Dec;60(13):3320-3323. doi: 10.1080/10428194.2019.1627540. Epub 2019 Jun 17.
Leuk Lymphoma. 2019.
PMID: 31204529
Free PMC article.
Clinical Trial.
No abstract available.
Item in Clipboard
Cite
Cite